Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologic Effects and Biomarkers of Nivolumab in Combination with Ipilimumab in Treatment-Naive Stage IV or Recurrent NSCLC
2018-000462-11Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoint: Primary endpoints Part 1. Started Apr 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-000462-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000462-11.